DK3281641T3 - Adjuvans til cancervacciner - Google Patents

Adjuvans til cancervacciner Download PDF

Info

Publication number: DK3281641T3
Authority: DK; Denmark
Prior art keywords: adjuvance; cancer vaccines; vaccines; cancer
Prior art date: 2015-04-07

Application number

DK16776655.9T

Other languages

English (en)

Inventor

Tomoya Miyakawa

Shun Doi

Koji Tamada

Original Assignee

Cytlimic Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-07

Filing date

2016-04-07

Publication date

2021-01-18

2016-04-07 Application filed by Cytlimic Inc filed Critical Cytlimic Inc

2021-01-18 Application granted granted Critical

2021-01-18 Publication of DK3281641T3 publication Critical patent/DK3281641T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Marine Sciences & Fisheries (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

DK16776655.9T 2015-04-07 2016-04-07 Adjuvans til cancervacciner DK3281641T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2015078684		2015-04-07
JP2015198066		2015-10-05
JP2016032046		2016-02-23
PCT/JP2016/061463 WO2016163489A1 (ja)	2015-04-07	2016-04-07	医薬

Publications (1)

Publication Number	Publication Date
DK3281641T3 true DK3281641T3 (da)	2021-01-18

Family

ID=57072456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16776655.9T DK3281641T3 (da)	2015-04-07	2016-04-07	Adjuvans til cancervacciner

Country Status (12)

Country	Link
US (2)	US10842848B2 (da)
EP (2)	EP3281641B1 (da)
JP (1)	JP6311094B2 (da)
CN (1)	CN107530432B (da)
AU (1)	AU2016244570B2 (da)
BR (1)	BR112017020404A2 (da)
CA (1)	CA2981468A1 (da)
DK (1)	DK3281641T3 (da)
ES (1)	ES2844049T3 (da)
RU (1)	RU2709015C2 (da)
TW (1)	TWI738646B (da)
WO (1)	WO2016163489A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6423889B2 (ja)	2014-10-07	2018-11-14	サイトリミック株式会社	Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3269733B1 (en)	2015-03-09	2020-06-17	Cytlimic Inc.	Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
US10842848B2 (en)	2015-04-07	2020-11-24	Cytlimic Inc.	Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
EP3527216B1 (en)	2016-10-11	2024-02-14	NEC Corporation	A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
JPWO2021106978A1 (da) *	2019-11-27	2021-06-03

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5196523A (en)	1985-01-01	1993-03-23	The University Of Southern California	Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja)	1994-11-28	1996-06-11	Teijin Ltd	Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0893507A1 (en) *	1997-07-25	1999-01-27	Institut Gustave Roussy	Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO2000037504A2 (en)	1998-12-23	2000-06-29	Pfizer Inc.	Human monoclonal antibodies to ctla-4
EP1212422B1 (en)	1999-08-24	2007-02-21	Medarex, Inc.	Human ctla-4 antibodies and their uses
AU2002212236A1 (en)	2000-09-13	2002-03-26	Gabriele Multhoff	An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO2003011895A2 (en)	2001-07-31	2003-02-13	Soederstroem Karl Petter	Compositions and methods for modulation of immune responses
AU2003254950A1 (en)	2002-08-26	2004-03-11	Kirin Beer Kabushiki Kaisha	Peptides and drugs containing the same
EP2572715A1 (en) *	2002-12-30	2013-03-27	3M Innovative Properties Company	Immunostimulatory Combinations
FR2863890B1 (fr) *	2003-12-19	2006-03-24	Aventis Pasteur	Composition immunostimulante
CN109485727A (zh)	2005-05-09	2019-03-19	小野药品工业株式会社	程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
AU2006248725A1 (en)	2005-05-19	2006-11-23	Glaxosmithkline Biologicals S.A.	Vaccine composition comprising B-subunit of E. coli heat toxin and an atigen and an adjuvant
KR101304243B1 (ko)	2005-08-09	2013-09-05	온코세라피 사이언스 가부시키가이샤	ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
WO2007119515A1 (ja)	2006-03-28	2007-10-25	Dainippon Sumitomo Pharma Co., Ltd.	新規腫瘍抗原ペプチド
RU2333767C2 (ru)	2006-03-31	2008-09-20	Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи")	Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
ES2545457T3 (es)	2006-10-17	2015-09-11	Oncotherapy Science, Inc.	Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
WO2008106491A2 (en)	2007-02-27	2008-09-04	University Of Utah Research Foundation	Peptides that interact with topoisomerase i and methods thereof
NZ600758A (en)	2007-06-18	2013-09-27	Merck Sharp & Dohme	Antibodies to human programmed death receptor pd-1
JP2010532785A (ja)	2007-07-06	2010-10-14	ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ．	炎症性疾患および自己免疫疾患の治療および予防
JP2010538655A (ja)	2007-09-12	2010-12-16	アナフォアインコーポレイテッド	自己免疫疾患についてのｈｓｐ７０に基づく治療
KR100900837B1 (ko) *	2007-12-07	2009-06-04	(주)두비엘	리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US9370558B2 (en)	2008-02-13	2016-06-21	President And Fellows Of Harvard College	Controlled delivery of TLR agonists in structural polymeric devices
WO2010077634A1 (en)	2008-12-09	2010-07-08	Genentech, Inc.	Anti-pd-l1 antibodies and their use to enhance t-cell function
MY163110A (en) *	2009-10-06	2017-08-15	Panacela Labs Llc	Use of toll-like receptor and agonist for treating cancer
NZ599405A (en)	2009-11-24	2014-09-26	Medimmune Ltd	Targeted binding agents against b7-h1
EP2785375B1 (en)	2011-11-28	2020-07-22	Merck Patent GmbH	Anti-pd-l1 antibodies and uses thereof
KR20140129124A (ko)	2012-02-07	2014-11-06	라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지	티모시 그라스 알레르겐들 및 면역반응 조절을 위한 방법들 및 용도들
US20130217122A1 (en)	2012-02-21	2013-08-22	The Trustees Of The University Of Pennsylvania	Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en)	2012-03-31	2013-10-03	Abmart (Shanghai) Co., Ltd	Peptide and antibody libraries and uses thereof
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN103961698A (zh)	2013-02-05	2014-08-06	日东电工株式会社	经皮或粘膜给予用疫苗组合物
RU2019138702A (ru)	2013-03-01	2020-01-27	Астекс Фармасьютикалз, Инк.	Комбинации лекарственных средств
US10682400B2 (en) *	2014-04-30	2020-06-16	President And Fellows Of Harvard College	Combination vaccine devices and methods of killing cancer cells
JP6423889B2 (ja)	2014-10-07	2018-11-14	サイトリミック株式会社	Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3269733B1 (en)	2015-03-09	2020-06-17	Cytlimic Inc.	Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
US10842848B2 (en)	2015-04-07	2020-11-24	Cytlimic Inc.	Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
WO2018021400A1 (ja)	2016-07-27	2018-02-01	国立大学法人北海道大学	がん免疫アジュバント
EP3527216B1 (en)	2016-10-11	2024-02-14	NEC Corporation	A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide

2016
- 2016-04-07 US US15/564,604 patent/US10842848B2/en active Active
- 2016-04-07 WO PCT/JP2016/061463 patent/WO2016163489A1/ja not_active Ceased
- 2016-04-07 DK DK16776655.9T patent/DK3281641T3/da active
- 2016-04-07 AU AU2016244570A patent/AU2016244570B2/en active Active
- 2016-04-07 ES ES16776655T patent/ES2844049T3/es active Active
- 2016-04-07 CA CA2981468A patent/CA2981468A1/en not_active Abandoned
- 2016-04-07 EP EP16776655.9A patent/EP3281641B1/en active Active
- 2016-04-07 RU RU2017134693A patent/RU2709015C2/ru active
- 2016-04-07 BR BR112017020404-5A patent/BR112017020404A2/pt not_active IP Right Cessation
- 2016-04-07 CN CN201680020132.8A patent/CN107530432B/zh not_active Expired - Fee Related
- 2016-04-07 EP EP20204940.9A patent/EP3797794A1/en not_active Withdrawn
- 2016-04-07 JP JP2017511073A patent/JP6311094B2/ja active Active
- 2016-04-07 TW TW105110968A patent/TWI738646B/zh not_active IP Right Cessation
2020
- 2020-07-22 US US16/935,534 patent/US11491204B2/en active Active

Also Published As

Publication number	Publication date
CA2981468A1 (en)	2016-10-13
US20210000916A1 (en)	2021-01-07
ES2844049T3 (es)	2021-07-21
AU2016244570A1 (en)	2017-10-05
EP3797794A1 (en)	2021-03-31
RU2709015C2 (ru)	2019-12-13
CN107530432B (zh)	2021-04-27
TWI738646B (zh)	2021-09-11
EP3281641A4 (en)	2018-12-19
JPWO2016163489A1 (ja)	2017-12-07
US11491204B2 (en)	2022-11-08
US10842848B2 (en)	2020-11-24
AU2016244570B2 (en)	2020-08-27
RU2017134693A (ru)	2019-04-04
WO2016163489A1 (ja)	2016-10-13
TW201642907A (zh)	2016-12-16
US20180071362A1 (en)	2018-03-15
EP3281641B1 (en)	2020-12-16
EP3281641A1 (en)	2018-02-14
BR112017020404A2 (pt)	2018-07-10
RU2017134693A3 (da)	2019-09-20
JP6311094B2 (ja)	2018-04-18
CN107530432A (zh)	2018-01-02

Publication	Publication Date	Title
FIC20230006I1 (fi)	2023-02-06	Vutrisiraani
IL255217A0 (en)	2017-12-31	Cancer neoepitopes
DK3393510T3 (da)	2023-03-13	Zikavirusvaccine
DK3240801T3 (da)	2021-02-08	Kombinationstumorimmunterapi
DK3594238T3 (da)	2021-04-19	Antistofsammensætninger til tumorbehandling
DK3204417T3 (da)	2020-10-12	Cd73-blokering
DK3072835T3 (da)	2019-07-29	Fremgangsmåde til fremføring
PT3298027T (pt)	2022-01-26	Compostos depsipéptidos antelmínticos
DK3186244T3 (da)	2020-07-13	Dioxolananaloger af uridin til behandling af cancer
DK3125898T3 (da)	2020-03-30	Farmakofor til trail-induktion
DK3199161T3 (da)	2022-01-03	Farmaceutisk præparat
DK3197890T3 (da)	2019-05-13	Disubstituerede diaryloxybenzoheterodiazolforbindelser
EP3310915A4 (en)	2019-04-10	TUMOR IMMUNOTHERAPY
HUE040167T2 (hu)	2019-02-28	Rákkezelés
LT3362444T (lt)	2021-06-25	Junginiai
DK3597189T3 (da)	2022-06-27	Krystallinske forbindelser
DK3281641T3 (da)	2021-01-18	Adjuvans til cancervacciner
DK3374357T3 (da)	2020-01-13	Disubstituerede diaryloxybenzoheterodiazol-forbindelser
DK3405212T3 (da)	2020-08-24	Cancervacciner
EP3372264A4 (en)	2019-07-03	SYRINGE
LT3331885T (lt)	2021-02-25	Junginiai
DK3155004T3 (da)	2021-04-06	Vaccine til immunkompromitterede værter
DK3277325T3 (da)	2021-01-18	Kombinationsimmunterapi for cancer
HUE050881T2 (hu)	2021-01-28	Gyógyszerkészítmény
IL260988A (en)	2018-10-31	Ptps-based vaccines against cancer